Literature DB >> 14534527

Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein.

Laura Spahn1, Christine Siligan, Radostina Bachmaier, Johannes A Schmid, Dave N T Aryee, Heinrich Kovar.   

Abstract

In Ewing's sarcoma family tumors, the ets transcription factor gene FLI1 is rearranged with one EWS allele resulting in coexpression of germline EWS and chimeric EWS-FLI1 proteins. Here, we investigated the potential of germline EWS, FLI1 and EWS-FLI1 to oligomerize. In two functional in vivo tests, fluorescence resonance energy transfer (FRET) and the mammalian two-hybrid (MTH) assay, self-association of EWS and EWS-FLI1, but not of FLI1 was detected. In addition, interaction of EWS-FLI1 with EWS and FLI1 was observed. GST pull-down assays and immunoprecipitation experiments largely confirmed these results. The EWS N-terminal domain present in both EWS and EWS-FLI1 was found to contribute to homotypic and heterotypic interactions of these proteins. However, in the context of germline EWS, the presence of the whole or part of the C-terminal RNA-binding domain greatly supported the self-association potential of the protein. Involvement of an RNA component in EWS oligomerization was confirmed by sensitivity of the corresponding GST pull-down assay to RNaseA treatment. In contrast, EWS-FLI1 was able to self-associate and also bind to FLI1 via its C-terminal domain, which comprises the FLI1 DNA-binding motif. Accordingly, the EWS-FLI1 interaction was not disrupted by RNaseA treatment. Despite its potential to oligomerize, EWS-FLI1 bound to a tandem ets-binding site of the TGFbeta type II receptor promoter as a monomer. Therefore, the functional consequences of homo- and hetero-oligomerization of EWS and EWS-FLI1 proteins remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534527     DOI: 10.1038/sj.onc.1206810

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  In vitro interaction between the N-terminus of the Ewing's sarcoma protein and the subunit of RNA polymerase II hsRPB7.

Authors:  Roumiana Todorova
Journal:  Mol Biol Rep       Date:  2008-07-08       Impact factor: 2.316

2.  Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain.

Authors:  Gaylor Boulay; Gabriel J Sandoval; Nicolo Riggi; Sowmya Iyer; Rémi Buisson; Beverly Naigles; Mary E Awad; Shruthi Rengarajan; Angela Volorio; Matthew J McBride; Liliane C Broye; Lee Zou; Ivan Stamenkovic; Cigall Kadoch; Miguel N Rivera
Journal:  Cell       Date:  2017-08-24       Impact factor: 41.582

3.  EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

Authors:  Aparna Gorthi; July Carolina Romero; Eva Loranc; Lin Cao; Liesl A Lawrence; Elicia Goodale; Amanda Balboni Iniguez; Xavier Bernard; V Pragathi Masamsetti; Sydney Roston; Elizabeth R Lawlor; Jeffrey A Toretsky; Kimberly Stegmaier; Stephen L Lessnick; Yidong Chen; Alexander J R Bishop
Journal:  Nature       Date:  2018-03-07       Impact factor: 49.962

4.  Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma.

Authors:  Nedjma Toub; Jean-Rémi Bertrand; Ali Tamaddon; Hind Elhamess; Hervé Hillaireau; Andrei Maksimenko; Jean Maccario; Claude Malvy; Elias Fattal; Patrick Couvreur
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

5.  Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma.

Authors:  Kunal Gangwal; Devin Close; Camille A Enriquez; Christopher P Hill; Stephen L Lessnick
Journal:  Genes Cancer       Date:  2010-02-01

6.  Interaction of the TNFR-receptor associated factor TRAF1 with I-kappa B kinase-2 and TRAF2 indicates a regulatory function for NF-kappa B signaling.

Authors:  Kalsoom Sughra; Andreas Birbach; Rainer de Martin; Johannes A Schmid
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

7.  EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma.

Authors:  Savita Sankar; Nicholas C Gomez; Russell Bell; Mukund Patel; Ian J Davis; Stephen L Lessnick; Wen Luo
Journal:  Genes Cancer       Date:  2013-05

Review 8.  Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions.

Authors:  Paul Jedlicka
Journal:  Int J Clin Exp Pathol       Date:  2010-03-19

9.  O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma.

Authors:  R Bachmaier; D N T Aryee; G Jug; M Kauer; M Kreppel; K A Lee; H Kovar
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

10.  Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines.

Authors:  Lisa J Embree; Mizuki Azuma; Dennis D Hickstein
Journal:  Cancer Res       Date:  2009-05-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.